Dr. Kaufman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-6786Fax+1 614-293-1470
Education & Training
- Duke University HospitalResidency, Internal Medicine, 2015 - 2018
- Vanderbilt University School of MedicineClass of 2015
Certifications & Licensure
- OH State Medical License 2021 - 2025
- NC State Medical License 2015 - 2021
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.Cameron Wood, Liliana Lyniv, James M Isaacs, Jacob M Kaufman, Eziafa I Oduah
Journal for Immunotherapy of Cancer. 2025-02-04 - CLO24-061: Overall Survival (OS) Impact for NSCLC Patients With irAE and Non-irAE Hospital Admissions During First-Line Pembrolizumab Treatment.Adam Khorasanchi, Songzhu Zhao, Lai Wei, Mingjia Li, Kevin Ho
Journal of the National Comprehensive Cancer Network. 2024-04-05 - 6 citationsA community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.Mike Mason, Óscar Lapuente-Santana, Anni S Halkola, Wenyu Wang, Raghvendra Mall
Journal of Translational Medicine. 2024-02-21
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: